June 2025

National Pharmacare: Canada’s Drug Agency Consulting on List of Essential Prescription Drugs

By Sarah Pennington, Paul Jorgensen & Kristin Wall on June 24, 2025

On June 19, 2025, Canada’s Drug Agency/L’Agence des médicaments du Canada (CDA-AMC) announced a consultation on a proposed list of essential prescription drugs and related products intended to inform the development of a national formulary. The consultation is…

Biosimilar drugs will no longer need phase 3 clinical trials: Proposed changes from Health Canada

By Paul Jorgensen, Pardeep Heir & Kristin Wall on June 20, 2025

Health Canada has proposed a substantial change to the regulation of biosimilar drugs in Canada that may result in earlier applications for marketing authorization and earlier litigation under the Patented Medicines (Notice of Compliance) Regulations (PMNOC Regulations). Specifically…

Pharma in Brief

June 2025

National Pharmacare: Canada’s Drug Agency Consulting on List of Essential Prescription Drugs

Biosimilar drugs will no longer need phase 3 clinical trials: Proposed changes from Health Canada

About

Topics

Archives